Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Drug combination delivers promising survival gains in advanced endometrial cancer (opens in a new tab)

news-medical.net · 2026-10-24

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

16 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Cited as backgroundpresented as the new finding

    https://www.mdanderson.org/newsroom/research-newsroom/esmo-2026--immunotherapy-combination-extends-survival-in-advanced-endometrial-cancer.h00-159859290.html

    Where the story links (opens in a new tab)
The literature search

16 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 12 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedAn immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib showed encouraging long-term survival outcomes in patients with advanced or recurrent endometrial cancer.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedIn the global Phase 3 DUO-E trial, durvalumab plus chemotherapy followed by durvalumab and olaparib achieved a median overall survival of 51.1 months, 11.5 months longer than chemotherapy alone.View evidenceHide evidence

As statedmedian overall survival of 51.1 months; 11.5 months longer than chemotherapy alone

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedThe trial randomized 718 patients with advanced or recurrent endometrial cancer to three regimens, and the current analysis evaluated overall survival and long-term safety after the study had already met its primary progression-free survival endpoints.View evidenceHide evidence

As stated718 patients

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedResearchers reported durable benefits on secondary endpoints, including longer time before subsequent therapy and longer time on treatment, and at 36 months 63.4% of patients in the durvalumab-plus-olaparib arm were alive versus 52% in the chemotherapy arm.View evidenceHide evidence

As stated63.4% alive at 36 months vs 52%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedNo new safety concerns were observed, and side effects remained consistent with previous findings.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe findings were presented at the European Society for Medical Oncology Congress 2026 by principal investigator Shannon Westin, M.D., of MD Anderson Cancer Center.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Explore all search results